183 related articles for article (PubMed ID: 25884806)
1. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.
Liu Y; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
BMC Cancer; 2015 Mar; 15():194. PubMed ID: 25884806
[TBL] [Abstract][Full Text] [Related]
2. A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women.
Liu Y; Liao J; Xu Y; Chen W; Liu D; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu X; Xie Y
Hum Mutat; 2011 Sep; 32(9):1000-3. PubMed ID: 21618645
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.
Pfeifer W; Sokolenko AP; Potapova ON; Bessonov AA; Ivantsov AO; Laptiev SA; Zaitseva OA; Yatsuk OS; Matsko DE; Semiglazova TY; Togo AV; Imyanitov EN
Breast Cancer Res Treat; 2014 Dec; 148(3):675-83. PubMed ID: 25414026
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
[TBL] [Abstract][Full Text] [Related]
5. Survival from breast cancer in patients with CHEK2 mutations.
Huzarski T; Cybulski C; Wokolorczyk D; Jakubowska A; Byrski T; Gronwald J; Domagała P; Szwiec M; Godlewski D; Kilar E; Marczyk E; Siołek M; Wiśniowski R; Janiszewska H; Surdyka D; Sibilski R; Sun P; Lubiński J; Narod SA
Breast Cancer Res Treat; 2014 Apr; 144(2):397-403. PubMed ID: 24557336
[TBL] [Abstract][Full Text] [Related]
6. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
[TBL] [Abstract][Full Text] [Related]
9. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Yuan H; Chen J; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2015 Oct; 21(19):4365-72. PubMed ID: 25979484
[TBL] [Abstract][Full Text] [Related]
10. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
[TBL] [Abstract][Full Text] [Related]
11. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
Näslund-Koch C; Nordestgaard BG; Bojesen SE
J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
[TBL] [Abstract][Full Text] [Related]
12. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
[TBL] [Abstract][Full Text] [Related]
13. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
[TBL] [Abstract][Full Text] [Related]
14. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.
Rainville I; Hatcher S; Rosenthal E; Larson K; Bernhisel R; Meek S; Gorringe H; Mundt E; Manley S
Breast Cancer Res Treat; 2020 Apr; 180(2):503-509. PubMed ID: 31993860
[TBL] [Abstract][Full Text] [Related]
15. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
[TBL] [Abstract][Full Text] [Related]
17. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
Kriege M; Hollestelle A; Jager A; Huijts PE; Berns EM; Sieuwerts AM; Meijer-van Gelder ME; Collée JM; Devilee P; Hooning MJ; Martens JW; Seynaeve C
Br J Cancer; 2014 Aug; 111(5):1004-13. PubMed ID: 24918820
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer.
Wang C; Zhang J; Wang Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2015 Mar; 26(3):523-8. PubMed ID: 25480878
[TBL] [Abstract][Full Text] [Related]
19. A Comparison between CHEK2*1100delC/I157T Mutation Carrier and Noncarrier Breast Cancer Patients: A Clinicopathological Analysis.
Huszno J; Budryk M; Kołosza Z; Tęcza K; Pamuła Piłat J; Nowara E; Grzybowska E
Oncology; 2016; 90(4):193-8. PubMed ID: 26991782
[TBL] [Abstract][Full Text] [Related]
20. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
